CP
GILD icon

Corbenic Partners’s Gilead Sciences GILD Stock Holding History

Corbenic Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50
Closed -$3K – 288
2021
Q3 		$3K Hold
50
– – ﹤0.01% 228
2021
Q2 		$3K Hold
50
– – ﹤0.01% 222
2021
Q1 		$3K Hold
50
– – ﹤0.01% 212
2020
Q4 		$3K Sell
50
-25
-33% -$1.51K ﹤0.01% 164
2020
Q3 		$5K Hold
75
– – ﹤0.01% 128
2020
Q2 		$6K Hold
75
– – ﹤0.01% 115
2020
Q1 		$6K Buy
+75
New +$5.18K ﹤0.01% 119
2017
Q4 		– Sell
-15
Closed -$1K – 206
2017
Q3 		$1K Buy
+15
New +$1.15K ﹤0.01% 247

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Corbenic Partners's GILD Position: Q4 2021 in Review

Corbenic Partners sold out of Gilead Sciences (GILD) in Q4 2021, closing a stake of 50 shares — an estimated $3K sold.

Corbenic Partners first reported a position in GILD in Q3 2017 and held it in 8 quarters. The position peaked at $6K in Q2 2020. 1,682 funds tracked by Wall St. Rank hold GILD as of Q4 2021.

  • Corbenic Partners reported no remaining Gilead Sciences position as of Q4 2021 after selling out during the quarter.
  • Corbenic Partners sold 50 Gilead Sciences shares in Q4 2021, an estimated $3K.
  • Corbenic Partners first reported a position in Gilead Sciences in Q3 2017 and held it in 8 quarters.
  • Corbenic Partners's Gilead Sciences position peaked at $6K in Q2 2020.
  • 1,682 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2021.

Based on Corbenic Partners's 13F filing for Q4 2021, filed 21 Jan 2022.